CABALETTA BIO Overview
Company Headquarters: Philadelphia, US
Founded: 2017
Workforce: ~ 10-50
Company Working: Cabaletta Bio (Cabaletta) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies (pathogenic B cells) while sparing normal B cells. The company’s CABA platform, has applicability across more than two dozen B cell-mediated autoimmune diseases.
Strategy
Focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, the Cabaletta has been granted orphan drug designation for the its lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop the CAAR T technology to treat B cell-mediated autoimmune diseases.
